Da Yang, MD, PhD has received a grant from the Elsa U. Pardee Foundation for a research project aimed at characterizing miR-506 as a novel therapy for ovarian cancer targeting metastasis and drug resistance. Tumor metastasis and drug resistances are the two biggest obstacles for improving ovarian cancer patients’ survival. The goal of Yang’s research is to identify novel therapy that can target ovarian cancer metastasis and drug resistance simultaneously.The insights generated by this study will result in a comprehensive understanding of ovarian cancer progression, and providing potential therapy for ovarian cancer patients.
Established in 1944, The Elsa U. Pardee Foundation funds prominent research group that formulates new approaches to treat and cure cancer.
Yang is an assistant professor in the pharmaceutical sciences department at the School of Pharmacy.
